Some answers, more questions for multi-cancer early detection tests

IF 52.5 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2026-09-22 DOI:10.1038/s41591-026-04688-w

Catherine R. Marinac, Timothy R. Rebbeck, Elizabeth K. O’Donnell

引用次数: 0

Abstract

The PATHFINDER 2 and NHS-Galleri studies provide complementary evidence on the clinical performance, safety and implementation of multi-cancer early detection, while underscoring the next challenge: demonstrating population-level benefit.

查看原文本刊更多论文

一些答案，更多的问题多癌早期检测测试

PATHFINDER 2和NHS-Galleri研究为多种癌症早期检测的临床表现、安全性和实施提供了补充证据，同时强调了下一个挑战：证明人群水平的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.